MET Kinase Inhibitor Reverses Resistance to Entrectinib Induced by Hepatocyte Growth Factor in Tumors with NTRK1 or ROS1 Rearrangements

Researchers investigated whether growth factors that may be produced by the microenvironment affect sensitivity of NTRK1-rearranged colon cancer KM12SM cells and ROS1-rearranged NSCLC HCC78 cells to entrectinib both in vitro and in vivo.